BioCentury | Aug 22, 2020
Translation in Brief

IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more

...listed as inventors on patents related to the switch technology, dubbed Co-LOCKR (Colocalization-dependent Latching Orthogonal Cage/Key...
BioCentury | May 29, 2020
Product Development

‘A science problem we can solve:’ a BioCentury podcast

...antibody could rescue non-human primates who are absolutely morbid lying on the bottom of the cage...
BioCentury | Apr 2, 2020
Product Development

COVID-19 roundup: EMA seeks to rein in chloroquine use; plus cash for CEPI, WHO’s SOLIDARITY grows, CytoDyn, EUSA, Chembio, PCR Biosystems and more

EMA said Wednesday that chloroquine and hydroxychloroquine should only be used to treat COVID-19 in clinical trials or national emergency use programs to preserve availability for autoimmune indications, such as lupus. The agency’s statement came...
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

...using a range of radioisotopes, targeting ligands, linkers and chelators -- chemical groups used to “cage”...
...to actinium 225, lead 212, thorium 227, lutetium 177 or copper 67, companies must first cage...
...“recoil” from releasing alpha particles can cause the radioisotope to fall out of its chelator cage...
BioCentury | Jan 13, 2020
Clinical News

Adaptimmune rises on early promise for SPEAR TCR cell therapies in solid tumors

...Alpha fetoprotein; MAGEA4 - Melanoma-associated antigen 4; MAGEA10 - Melanoma-associated antigen 10; NY-ESO-1 (CTAG1B) - Cancer/testis antigen...
BioCentury | Nov 7, 2019
Clinical News

First U.S. clinical CRISPR data give early safety signal for ex vivo editing

...mid-2020 of a systemically delivered CRISPR-based therapy for transthyretin amyloidosis (ATTR). Targets: NY-ESO-1 (CTAG1B) - Cancer/testis antigen...
...α chain; TCRB - T cell receptor β chain Lauren Martz, Associate Editor University of Pennsylvania Tmunity Therapeutics Inc. Cancer/testis antigen...
BioCentury | Nov 6, 2019
Financial News

A2 emerges with $57M series A, engineered T cells for solid tumors

...Solutions Inc.’s HuTARG technology for human antibody and human TCR engineering. A2’s lead program targets CAGE...
...last, but said the tranches are triggered by discovery and operational milestones. Targets: CAGE - Cancer/testis antigen...
BioCentury | Nov 1, 2019
Emerging Company Profile

Tmunity: Manufacturing momentum for CAR and TCR therapies

...necrosis factor (TNF) receptor superfamily member 9 MUC1 (CD227) - Mucin 1 NY-ESO-1 (CTAG1B) - Cancer/testis antigen...
...T cell receptor TGFβ - Type I transforming growth factor β Sandi Wong, Staff Writer Tmunity Therapeutics Inc. Cancer/testis antigen...
BioCentury | Oct 19, 2019
Product Development

How GSK has rebuilt its oncology pipeline from the ground up

...co-stimulator LAG3 (CD223) - Lymphocyte-activation gene 3 MHC - Major histocompatibility complex NY-ESO-1 (CTAG1B) - Cancer/testis antigen...
BioCentury | Oct 9, 2019
Company News

GSK partners with Lyell to bring gene, cell therapies into solid tumors

...could be applied to create programmable biologics and cell therapies. The system, dubbed latching orthogonal cage-key...
...who is now Grail’s CEO. Targets: CTAG2 (LAGE1; NY-ESO-2) - Cancer/testis antigen 2; NY-ESO-1 (CTAG1B) - Cancer/testis antigen...
...T-cell therapy (GSK3377794, enhanced T-cell therapy targeting NY-ESO-1, Enhanced TCR therapy targeting NY-ESO-1) Lyell Immunopharma Inc. GlaxoSmithKline plc Cancer/testis antigen...
Items per page:
1 - 10 of 158